Aggrenox® versus other pharmacotherapy in preventing recurrent stroke

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Expert Opinion on Pharmacotherapy

• Publication date

  2004-01-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1517/14656566.5.1.117PMID 14680441
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Antiplatelet therapy in cardiovascular disease

  2004cited by this paper
• Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial.

  2003influential reference
• Transient ischemic attack--proposal for a new definition.

  2002cited by this paper
• Is treatment with aspirin combined with dipyridamole really more cost-effective than aspirin alone?

  2001cited by this paper
• Cost-effectiveness of antiplatelet therapies.

  2001cited by this paper
• Cost-effectiveness of new antiplatelet regimens used as secondary prevention of stroke or transient ischemic attack.

  2000cited by this paper
• Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis.

  2000influential reference
• Thrombotic thrombocytopenic purpura associated with clopidogrel.

  2000cited by this paper
• Cost-effectiveness analysis of antiplatelet therapy in the prevention of recurrent stroke in the UK. Aspirin, dipyridamole and aspirin-dipyridamole.

  1999cited by this paper
• Supplement to the Guidelines for the Management of Transient Ischemic Attacks A Statement From the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association

  1999cited by this paper
• A metaregression analysis of the dose-response effect of aspirin on stroke.

  1999cited by this paper
• Number needed to treat (NNT).

  1999cited by this paper
• AHA Scientific Statement. Supplement to the guidelines for the management of transient ischemic attacks: A statement from the Ad Hoc Committee on Guidelines for the Management of Transient Ischemic Attacks, Stroke Council, American Heart Association.

  1999influential reference
• Antithrombotic and thrombolytic therapy for ischemic stroke.

  1998influential reference
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee

  1996cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

  1996cited by this paper
• Risk Factors for Stroke Mortality in Men and Women: The Busselton Study

  1996cited by this paper
• A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE)

  1996influential reference
• European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke.

  1996cited by this paper
• European Stroke Prevention Study 2

  1995influential reference
• Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.

  1994cited by this paper
• Collaborative overview of randomised trials of antiplatelet therapy Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients

  1994influential reference
• A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke.

  1991cited by this paper
• The European Stroke Prevention Study

  1991cited by this paper
• Probability of stroke: a risk profile from the Framingham Study.

  1991cited by this paper
• The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results.

  1991cited by this paper
• Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. The SALT Collaborative Group.

  1991influential reference
• European Stroke Prevention Study. ESPS Group.

  1990cited by this paper
• A randomized trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. Ticlopidine Aspirin Stroke Study Group.

  1989cited by this paper
• Drugs used for disorders of coagulation.

  1988cited by this paper
• Low‐dose acetylsalicylic acid (ASA) plus dipyridamole versus dipyridamole alone in the prevention of stroke in patients with reversible ischemic attacks

  1987cited by this paper
• Persantine aspirin trial in cerebral ischemia--Part III: Risk factors for stroke. The American-Canadian Co-Operative Study Group.

  1986cited by this paper
• Persantine Aspirin Trial in cerebral ischemia. Part II: Endpoint results. The American-Canadian Co-Operative Study group.

  1985cited by this paper
• "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of athero-thrombotic cerebral ischemia.

  1983cited by this paper
• Pharmacology of antiplatelet drugs and clinical trials on thrombosis prevention: a difficult link.

  1982cited by this paper
• Letter: Mentally subnormal children and their families.

  1973cited by this paper

• Secondary prevention of stroke.

  2009cites this paper
• Essential Psychopharmacology: The Prescriber's Guide

  2005cites this paper
• Acute stroke: evaluation and treatment.

  2005cites this paper